44 unknown, 34 recruiting, 30 completed, 19 terminated. 166 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 166 | Unknown 44, Recruiting 34, Completed 30, Terminated 19, Not yet recruiting 18, Active not recruiting 11, Withdrawn 6, Suspended 4 |
Follow Lymphoma: new trials by email Literature Review of Lymphoma trials Research Report on Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution APR-TD011 (RLF-TD011) - Cutaneous T Cell Lymphoma | Early Phase 1 | Not yet recruiting | Northwestern University | 30 | 2027-01-01 | 2026-05-01 |
| SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia SNC116 - B-cell Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | Shanghai Simnova Biotechnology Co.,Ltd. | 28 | 2026-09-01 | 2026-09-21 |
| GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma GoFast CD19 CAR T Cells - Relapsed or Refractory Large B-cell Lymphoma | Early Phase 1 | Not yet recruiting | Chinese PLA General Hospital | 9 | 2026-06-30 | 2026-06-26 |
| A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy humanized CD19 CAR-T Cells with TLR2 - B Lymphoblastic Leukemia/Lymphoma | Early Phase 1 | Not yet recruiting | Zhujiang Hospital | 60 | 2026-06-01 | 2026-01-12 |
| A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome Recombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder) - ARDS (Moderate or Severe), ARDS (Acute Respiratory Distress Syndrome) | Early Phase 1 | Recruiting | Shanghai Zhongshan Hospital | 24 | 2026-05-14 | 2026-06-11 |
| RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas RN1701 injection - Relapsed/Refractory B-cell Lymphoma | Early Phase 1 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 10 | 2026-05-08 | 2026-05-04 |
| Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors Methionine-Reduced Diet - Adenocarcinoma, Basal Cell Carcinoma | Early Phase 1 | Recruiting | University of California, Irvine | 25 | 2026-05-01 | 2026-07-31 |
| Exploratory Study on the Treatment of EB Virus Positive HIV Associated Lymphoma With EBV mRNA Vaccine EBV mRNA vaccine - HIV Associated Lymphoma | Early Phase 1 | Not yet recruiting | West China Hospital | 6 | 2026-05-01 | 2026-05-01 |
| Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma CD19/CD20 Tandem Dual CAR-T - Relapsed/Refractory B-Cell Lymphoma | Early Phase 1 | Not yet recruiting | Affiliated Hospital to Academy of Military Medical Sciences | 20 | 2026-04-30 | 2026-04-29 |
| A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma CT1182 injection - B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2026-04-30 | 2026-04-23 |
| Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma GI001 Injection - B-Cell Non-Hodgkin Lymphoma | Early Phase 1 | Not yet recruiting | Ruijin Hospital | 9 | 2026-04-20 | 2026-05-13 |
| CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation CAR19BCMA-T cells, fludarabine and cyclophosphamide - Relapsed or Refractory Plasma Cell Neoplasms, Lymphomas/Leukemias With Plasmacytic Differentiation | Early Phase 1 | Not yet recruiting | Affiliated Hospital to Academy of Military Medical Sciences | 20 | 2026-04-02 | 2026-04-08 |
| CD30 CAR-T in the Treatment of CD30 Positive Lymphoma chimeric antigen receptor gene modified T cells - Lymphoma, B Cell Lymphoma | Early Phase 1 | Suspended | Shandong Qilu Cell Therapy Engineering Technology Co., Ltd | 15 | 2026-03-01 | 2026-09-28 |
| Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia SYNCAR-100 Injection - B-Cell Acute Lymphoblastic Leukemia | Early Phase 1 | Recruiting | Zhejiang University | 16 | 2026-02-28 | 2026-02-24 |
| A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL) DT-7012 - Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides | Early Phase 1 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 30 | 2026-01-01 | 2025-10-09 |
| Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion - Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL) | Early Phase 1 | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 3 | 2025-12-31 | 2025-09-17 |
| A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma IMV101 treatment - Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Early Phase 1 | Recruiting | Suzhou Immunofoco Biotechnology Co., Ltd | 30 | 2025-12-29 | 2026-03-30 |
| Allogeneic UCB-derived CAR-T for B-ALL allogeneic umbilical cord blood-derived CAR-T - B-Cell Acute Lymphoblastic Leukemia, Adult | Early Phase 1 | Not yet recruiting | The General Hospital of Western Theater Command | 50 | 2025-12-01 | 2025-12-01 |
| Autologous Bedside CD19 CAR T-cell Therapy for B-ALL CD19 CAR T cells - B-Cell Acute Lymphoblastic Leukemia, Adult | Early Phase 1 | Not yet recruiting | The General Hospital of Western Theater Command | 50 | 2025-12-01 | 2025-12-11 |
| Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia GI001 - B-Cell Non-Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia | Early Phase 1 | Recruiting | Hematology department of the 920th hospital | 18 | 2025-11-28 | 2026-10-07 |
Showing 20 of 166. Sign in to see all of them.
Lymphoma, B-Cell (37) · Lymphoma, Non-Hodgkin (37) · Burkitt Lymphoma (29) · Lymphoma, Large B-Cell, Diffuse (21) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (21) · Lymphoma, Follicular (19) · Lymphoma, Mantle-Cell (15) · Recurrence (13) · Hodgkin Disease (12) · Multiple Myeloma (12) · Leukemia (11) · Leukemia, Lymphocytic, Chronic, B-Cell (11) · Lymphoma, T-Cell (9) · Lymphoma, T-Cell, Peripheral (8)
Hemic and Lymphatic Diseases (166) · Immune System Diseases (166) · Immunoproliferative Disorders (166) · Lymphatic Diseases (166) · Neoplasms by Histologic Type (166) · Lymphoproliferative Disorders (165) · Neoplasms (161) · Lymphoma, Non-Hodgkin (96) · Hematologic Diseases (51) · Lymphoma, B-Cell (43) · Leukemia (34) · Leukemia, Lymphoid (32) · DNA Virus Infections (31) · Herpesviridae Infections (31)
Cyclophosphamide (18) · Rituximab (10) · fludarabine (9) · Doxorubicin (5) · Etoposide (5) · Vincristine (5) · Immunotherapy, Adoptive (4) · Methotrexate (4) · Prednisone (4) · Radiotherapy (4) · pembrolizumab (4) · 68Ga-pentixafor (3) · Dexamethasone (3) · Filgrastim (3) · Granulocyte Colony-Stimulating Factor (3)
Zhejiang University (10) · He Huang (5) · M.D. Anderson Cancer Center (5) · Memorial Sloan Kettering Cancer Center (5) · Northwestern University (5) · Allife Medical Science and Technology Co., Ltd. (4) · Anhui Provincial Hospital (4) · Hebei Yanda Ludaopei Hospital (4) · Mayo Clinic (4) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (3) · Institute of Hematology & Blood Diseases Hospital, China (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Timmune Biotech Inc. (3) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (3) · University of Kansas Medical Center (3)
China (78) · United States (64) · Australia (2) · Canada (1) · Czechia (1) · Indonesia (1) · Spain (1) · Sweden (1)
Ariela Noy, MD (2) · Fang Liu, MD, PhD (2) · Farrokh Dehdashti, M.D. (2) · Hai Yi, M.D. & Ph.D. (2) · Hongyu Zhang, MD, PhD (2) · Jeffrey J. Raizer, MD (2) · Qingming Wang, M.D. (2) · Sunil Abhyankar, MD (2) · Xi Zhang, MD (2) · Yi Yao, ph.D (2) · Aaron Mangold (1) · Alan Zhou (1) · Ali Dana, MD (1) · Andrew M. Evens, DO, MS (1)
PMID 40540129, PMID 18042692, PMID 19880495, PMID 20671118, PMID 23023715, PMID 23649469, PMID 24142051, PMID 26202875, PMID 26222726, PMID 26353084, PMID 26424652, PMID 27269947, PMID 28911074, PMID 29652233, PMID 29920566, PMID 29925499, PMID 31776631, PMID 32840736, PMID 33242451, PMID 33851477, PMID 34344873, PMID 34435552, PMID 34651291, PMID 35468680, PMID 35973200, PMID 36189306, PMID 36719647, PMID 36808074, PMID 36923556, PMID 37077913, PMID 37093350, PMID 37192741, PMID 37781191, PMID 38143760, PMID 38592213, PMID 39563035, PMID 40311885, PMID 40406106, PMID 40574863, PMID 40940923, PMID 41110448, PMID 41194247, PMID 41538301, PMID 41633358, PMID 41776652, PMID 42255257, PMID 42490071, PMID 42845554
P30CA043703 (2), K12CA090433 (1), P30CA006973 (1), P30CA015083 (1), P30CA033572 (1), P30CA036727 (1), P30CA060553 (1), P30CA072720 (1), P30CA138292 (1), P50CA097274 (1), R01CA277493 (1), R42CA257797 (1), UM1CA121947 (1)